BRAF and thyroid cancer: A multicentric, randomized, open, phase 2 clinical trial revealed that the dabrafenib + trametinib combination was not superior in effectiveness to monotherapy with dabrafenib in patients with progressive BRAF-positive thyroid cancer refractory to radioactive iodine [14].